Protocol Ledger

NCT06435429 · Phase III · RECRUITING

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Interventional Phase III clinical trial protocol NCT06435429 sponsored by Jazz Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-13 Enrollment: 550 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06435429
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)550 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06435429
Protocol FieldVerified Registry Value
NCT IdentifierNCT06435429
Consolidated Lead SponsorJazz Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment550 participants (ESTIMATED)
Registered Start Date2024-08-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI